Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: BDR who wrote (1316)	12/25/1997 1:19:00 AM
From: Bill Wexler	Read Replies (1) \| Respond to of 7041

There will be no NDA filing... ...for the simple reason that Zonagen's clinical trials failed miserably. Phentolamine Mesylate is ineffective for the treatment of ED. They will not file an NDA because FDA rejection is 100% certain. Zonagen - of course - knew this. They have deliberately obfuscated the trial results for the sole purpose of keeping speculation alive and well. As long as speculation exists, the stock price remains artificially inflated while insiders cash out. Zonagen's additional tests and the vague asides about cancer in mice are simply new delaying tactics. There is no doubt that Zonagen is now a worthless enterprise - except for the cash they have in the bank. The stock price will eventually reflect that.